Canada's LGC Capital has termitaed its investment agreement with South African cannabis grower, House of Hemp. This comes after months of speculation and delays with regards to legislation and issuing of medical cannabis licenses in South Africa.
The Canadian investment firm has also indicated that as a result of legislative uncertainty, House of Hemp no longer meets its investment criteria.
"LGC has a number of very exciting projects that are now moving rapidly towards commercial medical cannabis production. These businesses are LGC's prime focus. We are looking forward to Little Green Pharma harvesting its first commercial crop in Australia in the next few weeks, and AAA Trichomes breaking ground at its new facility in Montreal over the coming weeks. In addition, LGC is working hard with the Global Canna Labs team in Jamaica to complete our detailed due diligence and assist its management team with its first commercial planting expected to commence next month. Italy's Evolution Bnk, which already has a cash flow, is on track to begin planting its first cannabis crops this summer. Our investments in Little Green Pharma and AAA Trichomes and our pending investments in Global Canna Labs and Evolution Bnk, in Australia, Canada, Jamaica and Italy, all have the potential for significant production of medical cannabis as each operation grows. Our CLV Frontier Brands joint venture with Creso Pharma Limited and Baltic Beer Company Ltd is on track to be in full commercial production and distribution this summer," said John McMullen, CEO at LGC.
The specific option that LGC has terminated and will not be exercising was for the acquisition of a 30% interest in House of Hemp. The company has also said that it is examining new near-term cash-flowing investment opportunities in Europe and Southern Africa.
"The South African Government has not put in place the legislative framework for the legalization of medical cannabis in that country. Although House of Hemp is still actively seeking a full set of commercial licenses, its lack of licenses at present means that it does not meet LGC's strict criteria for near-term production and cash-flow, As a result, House of Hemp no longer fits with LGC's investment objectives. LGC has a number of other investment opportunities that it believes will offer better short-term returns for its shareholders. The amounts invested by LGC in its due diligence review of House of Hemp were not material," reads a statement by LGC to investors.
LGC's interest in Southern Afrika's medical cannabis market seems to have spread to Lesotho and Zimbabwe where the Canafian investment firm is rumored to be possibly investing in some companies in those countries next.
"With respect to terminating the House of Hemp transaction, the absence of medical cannabis legislation in South Africa unfortunately means that House of Hemp's business is no longer one that suits LGC's business objectives of investing in near-term cash-flowing businesses. Not every investment LGC investigates will be concluded, and if businesses do not 100% stack-up for any reason whatsoever with respect to due diligence, budgets, timing or production potential, LGC will walk away from these opportunities to focus on better suited investment opportunities around the globe that meet our strict investment criteria," said McMullen.